Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report

Table 1 Reports of therapy-related leukemia development following oxaliplatin and/or capecitabine-containing chemotherapy

Ref.	Patient, age (yr)/gender	Primary cancer	Chemotherapy regimen	TRLs	Karyotype
Merrouche et al[12]	65/female	Colon	LVFU2, Irinotecan, OXP	APL	46,XX,add(6)(p23),-13,add(14)(p11),-16,add(17)(q?),-21,+3 mar
Carneiro et al[13]	56/female	Cecum	FOLFOX-4, FOLFOX-6	AML	Partial deletions of chromosomes 5, 7, 20, and 21, as well as trisomy 8 and loss of chromosomes 3 and 1
Merlin et al[14]	65/female	Colorectal	FOLFOX-4	ALL	Not available
Damodaran et al[15]	63/male	Esophagus	Capecitabine, OXP	AML	47,X,der(Y)t(Y;3)(q12;q21),+8(21)
Buxhofer-Ausch et al[16]	56/male	Colon	Capecitabine, 5-FU, Irinotecan, OXP	CML	Positive for Philadelphia chromosome
Kadikoylu et al[17]	66/male	Rectum	Cetuximab, OXP, Irinotecan, Capecitabine	CML	Positive for Philadelphia chromosome
Shapiro et al[18]	63/female	Cecum	Capecitabine	MLL	t(6;11) with breakpoint 11q23
Tansley et al[19]	66/male	Colon	Capecitabine	AML	Not available
Rashidi et al[20]	58/male	Rectum	Capecitabine, Radiation	APL	46,XY, t(15;17)(q24;q21)

APL: Acute promyelocytic leukemia; AML: Acute myeloid leukemia; ALL: Acute lymphoblastic leukemia; CML: Chronic myeloid leukemia; MLL: Chronic lymphoblastic leukemia; FOLFOX: Oxaliplatin plus 5-fluorouracil (5-FU); LVFU2: Leucovorin plus 5-FU; TRLs: Therapy-related leukemias.